New drug SYS6043 targets Hard-to-Treat cancers in early trial
NCT ID NCT07424547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early signs that the drug may slow tumor growth. About 386 participants will receive SYS6043 by IV every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYS6043 (a drug given by IV infusion that targets a tumor protein called B7-H3)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early phase 1 trial, so the main goals are safety and dosing — it is too soon to know if SYS6043 will effectively shrink tumors. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Global
RECRUITINGPlantation, Florida, 33322, United States
Contact
Contact Phone: •••-•••-••••
-
Florida Clinical Trials Group
RECRUITINGPlantation, Florida, 33322, United States
Contact
Contact Phone: •••-•••-••••
-
NEXT Oncology Austin
RECRUITINGAustin, Texas, 78758, United States
Contact
Contact Phone: •••-•••-••••
-
NEXT Oncology San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-••••